We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Developmental Drug Helps Protect Against Radiation Damage

By HospiMedica International staff writers
Posted on 19 May 2009
A drug currently under development has been shown to protect cells from the damaging effects of radiation exposure, a new study suggests. More...


The findings of the study were presented at the 100th annual meeting of the American Association for Cancer Research (AACR), April 18-22, 2009, in Denver, CO, USA. The study, led by Joel Greenberger, M.D., professor and chairman of the department of radiation Oncology at the University of Pittsburgh School of Medicine (Pitt; PA, USA), is overseen by Pitt's Center for Medical Countermeasures Against Radiation. The center is dedicated to identifying and developing small molecule radiation protectors and mitigators that can be easily accessed and administered in the event of a large-scale radiological or nuclear emergency.

JP4-039, the new developmental drug assists mitochondria, the energy generator of all cells, in combating irradiation-induced cell death. For this study, cells treated immediately after irradiation with JP4-039 demonstrated significant radioprotection, suggesting a potential role for the drug as a mitigator of radiation damage.

"Currently, no drugs on the market counteract the effects of radiation exposure,” said Dr. Greenberger. "We know this drug can counteract the damage caused by irradiation, and now we want to develop the ideal dosage, one that is effective for the general population while remaining nontoxic. Our goal is to take this drug through a phase I clinical trial, and once the dosage is established, develop the drug for late-stage clinical trials and market licensing.”

This study was funded by the Biomedical Advanced Research and Development Authority (BARDA), U.S. Department of Health and Human Services (Washington, DC, USA). In 2008, BARDA awarded Dr. Greenberger and members of his lab US$2.7 million to help develop a radiation mitigator drug that could counteract the effects of radiation exposure in case of large-scale public exposure. The ultimate goal of the contract is to develop an easily administered drug that the Centers for Disease Control and Prevention in the Department of Health and Human Services can store and fly to hospitals and care facilities if and when an emergency occurs.

Related Links:
University of Pittsburgh School of Medicine
Biomedical Advanced Research and Development Authority
Centers for Disease Control and Prevention


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
VTE Prevention System
Flowtron ACS900
Half Apron
Demi
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.